Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease
Open Access
- 28 November 2020
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 36 (2) , 481-491
Abstract
Objective: Identifying molecular changes that contribute to the onset and progression of Huntington's disease (HD) is of importance for the development and evaluation of potential therapies.Methods: We conducted an unbiased mass‐spectrometry proteomic analysis on the cerebrospinal fluid of 12 manifest HD patients (ManHD), 13 pre‐manifest (preHD), and 38 controls. A biologically plausible and significant possible biomarker was validated in samples from a separate cohort of patients and controls consisting of 23 ManHD patients and 23 controls.Results: In ManHD compared to preHD, 10 proteins were downregulated and 43 upregulated. Decreased levels of proenkephalin (PENK) and transthyretin were closely linked to HD symptom severity, whereas levels of 15 upregulated proteins were associated with symptom severity. The decreased PENK levels were replicated in the separate cohort where absolute quantitation was performed.Conclusions: We hypothesize that declining PENK levels reflect the degeneration of medium spiny neurons (MSNs) that produce PENK and that assays for PENK may serve as a surrogate marker for the state of MSNs in HD. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder SocietyKeywords
Funding Information
- Landstinget i Uppsala län
This publication has 42 references indexed in Scilit:
- Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptorsJournal of Medical Genetics, 2009
- Brain-specific Proteins Decline in the Cerebrospinal Fluid of Humans with Huntington DiseaseMolecular & Cellular Proteomics, 2009
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantificationNature Biotechnology, 2008
- Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's diseaseBrain, 2008
- A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's diseaseJournal of Experimental Medicine, 2008
- Proenkephalin expression and enkephalin release are widely observed in non-neuronal tissuesPeptides, 2008
- Proteomic Profiling of Plasma in Huntington's Disease Reveals Neuroinflammatory Activation and Biomarker CandidatesJournal of Proteome Research, 2007
- Proteome analysis of soluble nuclear proteins reveals that HMGB1/2 suppress genotoxic stress in polyglutamine diseasesNature Cell Biology, 2007
- A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG lengthClinical Genetics, 2004
- Cloning, developmental regulation and neural localization of rat ε-sarcoglycanMolecular Brain Research, 2003